Pharmac – Te Pātaka Whaioranga has announced that funding for continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables will be available for people with type 1 diabetes from 1 October 2024.
The decision includes funding:
a range of continuous glucose monitors (CGMs)
two brands of insulin pumps and automated insulin delivery (AID) system algorithms
the associated pump consumables
The funded devices include:
CGMs:
▪FreeStyle Libre 2 (standalone CGM)
▪FreeStyle Libre 3 Plus (interoperable with a funded insulin pump)
▪Dexcom G6 (interoperable with a funded insulin pump)
▪Dexcom G7 (interoperable with a funded insulin pump)
▪Dexcom One+ (standalone CGM)
Pumps:
▪Tandem t:slim x2 with Basal-IQ or Control-IQ (insulin pump, algorithm, and consumables)
▪mylife YpsoPump with CamAPS FX (insulin pump, algorithm, and consumables)